<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>VERAPAMIL HYDROCHLORIDE- verapamil hydrochloride tablet, film coated </strong><br>NCS HealthCare of KY, Inc dba Vangard Labs<br></p></div>
<h1>
<span class="Bold">Verapamil Hydrochloride Tablets USP</span><span class="Bold"><br></span>Revised: November 2008<br>Rx Only    174388</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_df21f294-eceb-47db-9945-ed81e97fff3a"></a><a name="section-1"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">Rx only</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="LINK_d58efa7b-dc9b-4787-b233-17342b2139cf"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Verapamil hydrochloride is a calcium ion influx inhibitor (slow-channel blocker or calcium ion antagonist) available for oral administration in film-coated tablets containing 40 mg, 80 mg or 120 mg of verapamil hydrochloride. Verapamil hydrochloride is not chemically related to other cardioactive drugs.</p>
<p>The structural formula of verapamil hydrochloride is:</p>
<div class="Figure"><img alt="The structural formula of verapamil hydrochloride " src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0c604923-4a37-45ac-ad93-3610a5eadc16&amp;name=verapamil-hydrochloride-tablets-1.jpg"></div>
<p>Benzeneacetonitrile, α-[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl]-3,4-dimethoxy-α-(1-methylethyl)-, monohydrochloride, (±)−</p>
<p>Verapamil hydrochloride is a white or practically white, crystalline powder. It is practically odorless and has a bitter taste. It is soluble in water, methanol, and chloroform.</p>
<p>The inactive ingredients are anhydrous lactose, corn starch, hypromellose 2910, magnesium stearate, microcrystalline cellulose, polacrilin potassium, and polyethylene glycol 400. In addition the following coloring agents are used: FD&amp;C Yellow No. 6 Aluminum Lake, hydroxypropyl cellulose and titanium dioxide (40 mg light peach, 80 mg light peach and 120 mg peach); hydroxypropyl cellulose and titanium dioxide (40 mg white, 80 mg white and 120 mg white).</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="LINK_07c2aa97-21a7-4f21-a96d-4d2562f3d7ec"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Verapamil hydrochloride is a calcium ion influx inhibitor (slow-channel blocker or calcium ion antagonist) that exerts its pharmacologic effects by modulating the influx of ionic calcium across the cell membrane of the arterial smooth muscle as well as in conductile and contractile myocardial cells.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_29c9306c-ab55-474e-9f8a-218e0a3d7368"></a><a name="section-3.1"></a><p></p>
<h2>Mechanism of action</h2>
<p class="First"><span class="Bold"><span class="Italics">Angina: </span></span>The precise mechanism of action of verapamil hydrochloride as an antianginal agent remains to be fully determined, but includes the following two mechanisms:</p>
<p>1<span class="Italics">. Relaxation and prevention of <span class="product-label-link" type="condition" conceptid="4127089" conceptname="Coronary artery spasm">coronary artery spasm</span>:</span> Verapamil dilates the main coronary arteries and coronary arterioles, both in normal and ischemic regions, and is a potent inhibitor of <span class="product-label-link" type="condition" conceptid="4127089" conceptname="Coronary artery spasm">coronary artery spasm</span>, whether spontaneous or ergonovine-induced. This property increases myocardial oxygen delivery in patients with <span class="product-label-link" type="condition" conceptid="4127089" conceptname="Coronary artery spasm">coronary artery spasm</span> and is responsible for the effectiveness of verapamil in vasospastic (Prinzmetal’s or variant) as well as <span class="product-label-link" type="condition" conceptid="315296" conceptname="Preinfarction syndrome">unstable angina</span> at rest. Whether this effect plays any role in classical effort angina is not clear, but studies of exercise tolerance have not shown an increase in the maximum exercise rate-pressure product, a widely accepted measure of oxygen utilization. This suggests that, in general, relief of spasm or dilation of coronary arteries is not an important factor in classical angina.</p>
<p>2<span class="Italics">. Reduction of oxygen utilization:</span> Verapamil regularly reduces the total peripheral resistance (afterload) against which the heart works both at rest and at a given level of exercise by dilating peripheral arterioles. This unloading of the heart reduces myocardial energy consumption and oxygen requirements and probably accounts for the effectiveness of verapamil in chronic stable effort angina.</p>
<p><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Arrhythmia</span>:</span></span> Electrical activity through the AV node depends, to a significant degree, upon calcium influx through the slow channel. By decreasing the influx of calcium, verapamil prolongs the effective refractory period within the AV node and slows AV conduction in a rate-related manner. This property accounts for the ability of verapamil to slow the ventricular rate in patients with chronic <span class="product-label-link" type="condition" conceptid="314665" conceptname="Atrial flutter">atrial flutter</span> or <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>.</p>
<p>Normal sinus rhythm is usually not affected, but in patients with <span class="product-label-link" type="condition" conceptid="317302" conceptname="Sinus node dysfunction">sick sinus syndrome</span>, verapamil may interfere with sinus-node impulse generation and may induce <span class="product-label-link" type="condition" conceptid="4210313" conceptname="Sinus arrest">sinus arrest</span> or <span class="product-label-link" type="condition" conceptid="4277903" conceptname="Sinoatrial block">sinoatrial block</span>. <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">Atrioventricular block</span> can occur in patients without preexisting conduction defects (see <a href="#LINK_edcbe031-4dbb-41e3-a9ae-93862738a56a">WARNINGS</a>). Verapamil decreases the frequency of episodes of <span class="product-label-link" type="condition" conceptid="317893" conceptname="Paroxysmal supraventricular tachycardia">paroxysmal supraventricular tachycardia</span>.</p>
<p>Verapamil does not alter the normal atrial action potential or intraventricular conduction time, but in depressed atrial fibers it decreases amplitude, velocity of depolarization, and conduction velocity. Verapamil may shorten the antegrade effective refractory period of the accessory bypass tract. Acceleration of ventricular rate and/or <span class="product-label-link" type="condition" conceptid="437894" conceptname="Ventricular fibrillation">ventricular fibrillation</span> has been reported in patients with <span class="product-label-link" type="condition" conceptid="314665" conceptname="Atrial flutter">atrial flutter</span> or <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span> and a coexisting accessory AV pathway following administration of verapamil (see <a href="#LINK_edcbe031-4dbb-41e3-a9ae-93862738a56a">WARNINGS</a>).</p>
<p>Verapamil has a local anesthetic action that is 1.6 times that of procaine on an equimolar basis. It is not known whether this action is important at the doses used in man.</p>
<p><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="320128" conceptname="Essential hypertension">Essential hypertension</span>: </span></span>Verapamil exerts antihypertensive effects by decreasing systemic <span class="product-label-link" type="condition" conceptid="4089490" conceptname="Vascular resistance">vascular resistance</span>, usually without orthostatic decreases in blood pressure or <span class="product-label-link" type="condition" conceptid="444070" conceptname="Tachycardia">reflex tachycardia</span>; <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> (rate less than 50 beats/min) is uncommon (1.4%). During isometric or dynamic exercise verapamil does not alter systolic cardiac function in patients with normal ventricular function.</p>
<p>Verapamil does not alter total serum calcium levels. However, one report suggested that calcium levels above the normal range may alter the therapeutic effect of verapamil.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_034612d6-98e3-450d-9f20-481ac75036e7"></a><a name="section-3.2"></a><p></p>
<h2>Pharmacokinetics and metabolism</h2>
<p class="First">More than 90% of the orally administered dose of verapamil hydrochloride is absorbed. Because of rapid biotransformation of verapamil during its first pass through the portal circulation, bioavailability ranges from 20% to 35%. Peak plasma concentrations are reached between 1 and 2 hours after oral administration. Chronic oral administration of 120 mg of verapamil hydrochloride every 6 hours resulted in plasma levels of verapamil ranging from 125 to 400 ng/mL, with higher values reported occasionally. A nonlinear correlation between the verapamil dose administered and verapamil plasma levels does exist. No relationship has been established between the plasma concentration of verapamil and a reduction in blood pressure. In early dose titration with verapamil a relationship exists between verapamil plasma concentration and prolongation of the PR interval. However, during chronic administration this relationship may disappear. The mean elimination half-life in single-dose studies ranged from 2.8 to 7.4 hours. In these same studies, after repetitive dosing, the half-life increased to a range from 4.5 to 12 hours (after less than 10 consecutive doses given 6 hours apart). Half-life of verapamil may increase during titration. Aging may affect the pharmacokinetics of verapamil. Elimination half-life may be prolonged in the elderly. In healthy men, orally administered verapamil hydrochloride undergoes extensive metabolism in the liver. Twelve metabolites have been identified in plasma; all except norverapamil are present in trace amounts only. Norverapamil can reach steady-state plasma concentrations approximately equal to those of verapamil itself. The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil. Approximately 70% of an administered dose is excreted as metabolites in the urine and 16% or more in the feces within 5 days. About 3% to 4% is excreted in the urine as unchanged drug. Approximately 90% is bound to plasma proteins. In patients with <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span>, metabolism is delayed and elimination half-life prolonged up to 14 to 16 hours (see <a href="#LINK_a6e74a32-533b-43a2-b01a-36edd6622d06">PRECAUTIONS</a>); the volume of distribution is increased and plasma clearance reduced to about 30% of normal. Verapamil clearance values suggest that patients with liver dysfunction may attain therapeutic verapamil plasma concentrations with one third of the oral daily dose required for patients with normal liver functions.</p>
<p>After four weeks of oral dosing (120 mg q.i.d.), verapamil and norverapamil levels were noted in the cerebrospinal fluid with estimated partition coefficient of 0.06 for verapamil and 0.04 for norverapamil.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_ab3b0668-509d-46ec-bd68-959f1ec934d5"></a><a name="section-3.3"></a><p></p>
<h2>Hemodynamics and myocardial metabolism</h2>
<p class="First">Verapamil reduces afterload and myocardial contractility. Improved left ventricular diastolic function in patients with <span class="product-label-link" type="condition" conceptid="4124693" conceptname="Hypertrophic cardiomyopathy">IHSS</span> and those with coronary heart disease has also been observed with verapamil hydrochloride therapy. In most patients, including those with organic cardiac disease, the negative inotropic action of verapamil is countered by reduction of afterload, and <span class="product-label-link" type="condition" conceptid="4208254" conceptname="Cardiac index">cardiac index</span> is usually not reduced. However, in patients with severe <span class="product-label-link" type="condition" conceptid="4047088" conceptname="Left ventricular systolic dysfunction">left ventricular dysfunction</span> (e.g., pulmonary wedge pressure above 20 mm Hg or <span class="product-label-link" type="condition" conceptid="4108582" conceptname="Left ventricular ejection fraction">ejection fraction</span> less than 30%), or in patients taking beta-adrenergic blocking agents or other cardiodepressant drugs, deterioration of ventricular function may occur (see <a href="#LINK_c79e2003-3467-42ac-a921-17aabd811ad3">Drug interactions</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_3974cdd7-5e34-4689-ae09-62dbdbeb6542"></a><a name="section-3.4"></a><p></p>
<h2>Pulmonary function</h2>
<p class="First">Verapamil does not induce <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchoconstriction</span> and, hence, does not impair ventilatory function.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="LINK_1deba9d7-84ce-43e1-bcd4-ad8539ce128d"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Verapamil Hydrochloride Tablets are indicated for the treatment of the following:</p>
<p><span class="Bold">Angina</span></p>
<p>1.	Angina at rest including:</p>
<p>–	Vasospastic (Prinzmetal’s variant) angina</p>
<p>–	Unstable (crescendo, pre-<span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">infarction</span>) angina</p>
<p>2.	Chronic stable angina (classic effort-associated angina)</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Arrhythmias</span></span></p>
<p>1.	In association with digitalis for the control of ventricular rate at rest and during stress in patients with chronic <span class="product-label-link" type="condition" conceptid="314665" conceptname="Atrial flutter">atrial flutter</span> and/or <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span> (see <a href="#LINK_28ef7731-3b49-4e0b-aeb3-cc8915628810">WARNINGS</a>; <a href="#LINK_28ef7731-3b49-4e0b-aeb3-cc8915628810">Accessory Bypass Tract</a>)</p>
<p>2.	Prophylaxis of repetitive <span class="product-label-link" type="condition" conceptid="317893" conceptname="Paroxysmal supraventricular tachycardia">paroxysmal supraventricular tachycardia</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="320128" conceptname="Essential hypertension">Essential Hypertension</span></span></p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="LINK_d8578d44-9ad9-4fef-b7b8-4cd7acec2ff5"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Verapamil Hydrochloride Tablets are contraindicated in:</p>
<p>1. Severe <span class="product-label-link" type="condition" conceptid="4047088" conceptname="Left ventricular systolic dysfunction">left ventricular dysfunction</span> (see <a href="#LINK_edcbe031-4dbb-41e3-a9ae-93862738a56a">WARNINGS</a>)</p>
<p>2. <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> (systolic pressure less than 90 mm Hg) or <span class="product-label-link" type="condition" conceptid="198571" conceptname="Cardiogenic shock">cardiogenic shock</span></p>
<p>3. <span class="product-label-link" type="condition" conceptid="317302" conceptname="Sinus node dysfunction">Sick sinus syndrome</span> (except in patients with a functioning artificial ventricular pacemaker)</p>
<p>4. Second-or-third-degree <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">AV block</span> (except in patients with a functioning artificial ventricular pacemaker)</p>
<p>5. Patients with <span class="product-label-link" type="condition" conceptid="314665" conceptname="Atrial flutter">atrial flutter</span> or <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span> and an accessory bypass tract (e.g., Wolff-Parkinson-White, Lown-Ganong-Levine syndromes). (see <a href="#LINK_edcbe031-4dbb-41e3-a9ae-93862738a56a">WARNINGS</a>)</p>
<p>6. Patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to verapamil hydrochloride.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="LINK_edcbe031-4dbb-41e3-a9ae-93862738a56a"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_48bd1252-08e4-416e-b67b-353efd29e3e3"></a><a name="section-6.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart failure</span></h2>
<p class="First">Verapamil has a negative inotropic effect, which in most patients is compensated by its afterload reduction (decreased systemic <span class="product-label-link" type="condition" conceptid="4089490" conceptname="Vascular resistance">vascular resistance</span>) properties without a net impairment of ventricular performance. In clinical experience with 4,954 patients, 87 (1.8%) developed <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> or <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>. Verapamil should be avoided in patients with severe <span class="product-label-link" type="condition" conceptid="4047088" conceptname="Left ventricular systolic dysfunction">left ventricular dysfunction</span> (e.g., <span class="product-label-link" type="condition" conceptid="4108582" conceptname="Left ventricular ejection fraction">ejection fraction</span> less than 30%) or moderate to severe symptoms of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span> and in patients with any degree of ventricular dysfunction if they are receiving a beta-adrenergic blocker (see <a href="#LINK_c79e2003-3467-42ac-a921-17aabd811ad3">Drug interactions</a>). Patients with milder ventricular dysfunction should, if possible, be controlled with optimum doses of digitalis and/or diuretics before verapamil treatment. (<span class="Bold">Note interactions with digoxin under PRECAUTIONS</span>.)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_0bd38b49-57ea-4cc1-b998-a4c8a54456d4"></a><a name="section-6.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></h2>
<p class="First">Occasionally, the pharmacologic action of verapamil may produce a decrease in blood pressure below normal levels, which may result in <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> or symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. The incidence of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> observed in 4,954 patients enrolled in clinical trials was 2.5%. In hypertensive patients, decreases in blood pressure below normal are unusual. Tilt-table testing (60 degrees) was not able to induce <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_3e9df2a1-695c-47a2-be9b-b2763955ac0a"></a><a name="section-6.3"></a><p></p>
<h2>Elevated liver enzymes</h2>
<p class="First">Elevations of transaminases with and without concomitant elevations in alkaline phosphatase and bilirubin have been reported. Such elevations have sometimes been transient and may disappear even with continued verapamil treatment. Several cases of <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">hepatocellular injury</span> related to verapamil have been proven by rechallenge; half of these had clinical symptoms (<span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, and/or <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">right upper quadrant pain</span>), in addition to elevation of <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>, SGPT, and alkaline phosphatase. Periodic monitoring of liver function in patients receiving verapamil is therefore prudent.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_28ef7731-3b49-4e0b-aeb3-cc8915628810"></a><a name="section-6.4"></a><p></p>
<h2>Accessory bypass tract (Wolff-Parkinson-White or Lown-Ganong-Levine)</h2>
<p class="First">Some patients with paroxysmal and/or <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">chronic atrial fibrillation</span> or <span class="product-label-link" type="condition" conceptid="314665" conceptname="Atrial flutter">atrial flutter</span> and a coexisting accessory AV pathway have developed increased antegrade conduction across the accessory pathway bypassing the AV node, producing a very rapid ventricular response or <span class="product-label-link" type="condition" conceptid="437894" conceptname="Ventricular fibrillation">ventricular fibrillation</span> after receiving intravenous verapamil (or digitalis). Although a risk of this occurring with oral verapamil has not been established, such patients receiving oral verapamil may be at risk and its use in these patients is contraindicated (see <a href="#LINK_d8578d44-9ad9-4fef-b7b8-4cd7acec2ff5">CONTRAINDICATIONS</a>). Treatment is usually DC-cardioversion. Cardioversion has been used safely and effectively after oral verapamil hydrochloride.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_b690ee57-8cef-4d2a-9315-a717aa9fa55b"></a><a name="section-6.5"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">Atrioventricular block</span></h2>
<p class="First">The effect of verapamil on AV conduction and the SA mode may cause asymptomatic first-degree <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">AV block</span> and transient <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, sometimes accompanied by nodal escape rhythms. PR-interval prolongation is correlated with verapamil plasma concentrations especially during the early titration phase of therapy. Higher degrees of <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">AV block</span>, however, were infrequently (0.8%) observed. Marked first-degree block or progressive development to second-or-third-degree <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">AV block</span> requires a reduction in dosage or, in rare instances, discontinuation of verapamil hydrochloride and institution of appropriate therapy, depending on the clinical situation.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_828f961a-be27-42af-81ea-0df21e1133bd"></a><a name="section-6.6"></a><p></p>
<h2>Patients with <span class="product-label-link" type="condition" conceptid="4124693" conceptname="Hypertrophic cardiomyopathy">hypertrophic cardiomyopathy</span> (<span class="product-label-link" type="condition" conceptid="4124693" conceptname="Hypertrophic cardiomyopathy">IHSS</span>)</h2>
<p class="First">In 120 patients with <span class="product-label-link" type="condition" conceptid="4124693" conceptname="Hypertrophic cardiomyopathy">hypertrophic cardiomyopathy</span> (most of them refractory or intolerant to propranolol) who received therapy with verapamil at doses up to 720 mg/day, a variety of serious adverse effects was seen. Three patients died in <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>; all had severe left ventricular outflow obstruction and a past history of <span class="product-label-link" type="condition" conceptid="4047088" conceptname="Left ventricular systolic dysfunction">left ventricular dysfunction</span>. Eight other patients had <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span> and/or severe <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>; abnormally high (greater than 20 mm Hg) pulmonary wedge pressure and a marked left ventricular outflow obstruction were present in most of these patients. Concomitant administration of quinidine (see <a href="#LINK_c79e2003-3467-42ac-a921-17aabd811ad3">Drug interactions</a>) preceded the severe <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> in 3 of the 8 patients (2 of whom developed <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>). <span class="product-label-link" type="condition" conceptid="4171683" conceptname="Sinus bradycardia">Sinus bradycardia</span> occurred in 11% of the patients, second-degree <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">AV block</span> in 4%, and <span class="product-label-link" type="condition" conceptid="4210313" conceptname="Sinus arrest">sinus arrest</span> in 2%. It must be appreciated that this group of patients had a serious disease with a high mortality rate. Most adverse effects responded well to dose reduction, and only rarely did verapamil use have to be discontinued.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="LINK_a6e74a32-533b-43a2-b01a-36edd6622d06"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="LINK_4be6b2a1-e394-4681-a0c6-ebc046c33790"></a><a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First"><span class="Bold">Use in patients with impaired hepatic function: </span>Since verapamil is highly metabolized by the liver, it should be administered cautiously to patients with impaired hepatic function. Severe liver dysfunction prolongs the elimination half-life of verapamil to about 14 to 16 hours; hence, approximately 30% of the dose given to patients with normal liver function should be administered to these patients. Careful monitoring for abnormal prolongation of the PR interval or other signs of excessive pharmacologic effects (see <a href="#LINK_3ce20d87-ca48-4a72-9d74-1075bbfdfa12">OVERDOSAGE</a>) should be carried out.</p>
<p><span class="Bold">Use in patients with attenuated (decreased) neuromuscular transmission:</span> It has been reported that verapamil decreases neuromuscular transmission in patients with Duchenne’s <span class="product-label-link" type="condition" conceptid="4247802" conceptname="Muscular dystrophy">muscular dystrophy</span>, and that verapamil prolongs recovery from the neuromuscular blocking agent vecuronium. It may be necessary to decrease the dosage of verapamil when it is administered to patients with attenuated neuromuscular transmission.</p>
<p><span class="Bold">Use in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>:</span> About 70% of an administered dose of verapamil is excreted as metabolites in the urine. Verapamil is not removed by hemodialysis. Until further data are available, verapamil should be administered cautiously to patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. These patients should be carefully monitored for abnormal prolongation of the PR interval or other signs of overdosage (see <a href="#LINK_3ce20d87-ca48-4a72-9d74-1075bbfdfa12">OVERDOSAGE</a>).</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="LINK_c79e2003-3467-42ac-a921-17aabd811ad3"></a><a name="section-7.2"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First"><span class="Bold">Alcohol:</span> Verapamil may increase blood alcohol concentrations and prolong its effects.</p>
<p><span class="Bold">Beta-blockers: </span>Controlled studies in small numbers of patients suggest that the concomitant use of verapamil hydrochloride and oral beta-adrenergic blocking agents may be beneficial in certain patients with chronic stable angina or <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, but available information is not sufficient to predict with confidence the effects of concurrent treatment in patients with <span class="product-label-link" type="condition" conceptid="4047088" conceptname="Left ventricular systolic dysfunction">left ventricular dysfunction</span> or cardiac conduction abnormalities. Concomitant therapy with beta-adrenergic blockers and verapamil may result in additive negative effects on heart rate, atrioventricular conduction and/or cardiac contract contractility.</p>
<p>In one study involving 15 patients treated with high doses of propranolol (median dose, 480 mg/day; range, 160 to 1,280 mg/day) for severe angina, with preserved left ventricular function (<span class="product-label-link" type="condition" conceptid="4108582" conceptname="Left ventricular ejection fraction">ejection fraction</span> greater than 35%), the hemodynamic effects of additional therapy with verapamil hydrochloride were assessed using invasive methods. The addition of verapamil to high-dose beta-blockers induced modest negative inotropic and chronotropic effects that were not severe enough to limit short-term (48 hours) combination therapy in this study. These modest cardiodepressant effects persisted for greater than 6, but less than 30 hours after abrupt withdrawal of beta-blockers and were closely related to plasma levels of propranolol. The primary verapamil/beta-blocker interaction in this study appeared to be hemodynamic rather than electrophysiologic.</p>
<p>In other studies verapamil did not generally induce significant negative inotropic, chronotropic, or dromotropic effects in patients with preserved left ventricular function receiving low or moderate doses of propranolol (less than or equal to 320 mg/day); in some patients, however, combined therapy did produce such effects. Therefore, if combined therapy is used, close surveillance of clinical status should be carried out. Combined therapy should usually be avoided in patients with atrioventricular conduction abnormalities and those with depressed left ventricular function.</p>
<p>Asymptomatic <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> (36 beats/min) with a <span class="product-label-link" type="condition" conceptid="4111551" conceptname="Wandering atrial pacemaker">wandering atrial pacemaker</span> has been observed in a patient receiving concomitant timolol (a beta-adrenergic blocker) eyedrops and oral verapamil.</p>
<p>A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil. A variable effect has been seen when verapamil and atenolol were given together.</p>
<p><span class="Bold">Digitalis:</span> Clinical use of verapamil in digitalized patients has shown the combination to be well tolerated if digoxin doses are properly adjusted. However, chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digitalis toxicity</span>. In patients with <span class="product-label-link" type="condition" conceptid="4064161" conceptname="Cirrhosis of liver">hepatic cirrhosis</span> the influence of verapamil on digitoxin kinetics is magnified. Verapamil may reduce total body clearance and extrarenal clearance of digitoxin by 27% and 29% respectively. Maintenance and digitalization doses should be reduced when verapamil is administered, and the patient should be reassessed to avoid over- or underdigitalization. Whenever overdigitalization is suspected, the daily dose of digitalis should be reduced or temporary discontinued. On discontinuation of verapamil hydrochloride use, the patient should be reassessed to avoid underdigitalization.</p>
<p><span class="Bold">Antihypertensive agents:</span> Verapamil administered concomitantly with oral antihypertensive agents (e.g., vasodilators, angiotensin-converting enzyme inhibitors, diuretics, beta-blockers) will usually have an additive effect on lowering blood pressure. Patients receiving these combinations should be appropriately monitored. Concomitant use of agents that attenuate alpha-adrenergic function with verapamil may result in a reduction in blood pressure that is excessive in some patients. Such an effect was observed in one study following the concomitant administration of verapamil and prazosin.</p>
<p><span class="Bold">Antiarrhythmic agents:</span></p>
<p><span class="Bold"><span class="Underline">Disopyramide:</span></span> Until data on possible interactions between verapamil and disopyramide are obtained, disopyramide should not be administered within 48 hours before or 24 hours after verapamil administration.</p>
<p><span class="Bold">Flecainide:</span> A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction, and repolarization. Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.</p>
<p><span class="Bold"><span class="Underline">Quinidine:</span></span> In a small number of patients with <span class="product-label-link" type="condition" conceptid="4124693" conceptname="Hypertrophic cardiomyopathy">hypertrophic cardiomyopathy</span> (<span class="product-label-link" type="condition" conceptid="4124693" conceptname="Hypertrophic cardiomyopathy">IHSS</span>) concomitant use of verapamil and quinidine resulted in significant <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. Until further data are obtained, combined therapy of verapamil and quinidine in patients with <span class="product-label-link" type="condition" conceptid="4124693" conceptname="Hypertrophic cardiomyopathy">hypertrophic cardiomyopathy</span> should probably be avoided.</p>
<p>The electrophysiologic effects of quinidine and verapamil on AV conduction were studied in 8 patients. Verapamil significantly counteracted the effects of quinidine on AV conduction. There has been a report of increased quinidine levels during verapamil therapy.</p>
<p><span class="Bold">Other:</span></p>
<p><span class="Bold"><span class="Underline">Nitrates: </span></span>Verapamil has been given concomitantly with short- and long-acting nitrates without any undesirable drug interactions. The pharmacologic profile of both drugs and the clinical experience suggest beneficial interactions.</p>
<p><span class="Bold"><span class="Underline">Cimetidine:</span></span> The interaction between cimetidine and chronically administered verapamil has not been studied. Variable results on clearance have been obtained in acute studies of healthy volunteers; clearance of verapamil was either reduced of unchanged.</p>
<p><span class="Bold"><span class="Underline">Lithium:</span></span> Increased sensitivity to the effects of lithium (<span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">neurotoxicity</span>) has been reported during concomitant verapamil-lithium therapy; lithium levels have been observed sometimes to increase, sometimes to decrease, and sometimes to be unchanged. Patients receiving both drugs must be monitored carefully.</p>
<p><span class="Bold"><span class="Underline">Carbamazepine: </span></span>Verapamil therapy may increase carbamazepine concentrations during combined therapy. This may produce carbamazepine side effects such as <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, or <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>.</p>
<p><span class="Bold"><span class="Underline">Rifampin:</span></span> Therapy with rifampin may markedly reduce oral verapamil bioavailability.</p>
<p><span class="Bold"><span class="Underline">Phenobarbital:</span></span> Phenobarbital therapy may increase verapamil clearance.</p>
<p><span class="Bold"><span class="Underline">Cyclosporin:</span></span> Verapamil therapy may increase serum levels of cyclosporin.</p>
<p><span class="Bold"><span class="Underline">Theophylline:</span></span> Verapamil may inhibit the clearance and increase the plasma levels of theophylline.</p>
<p><span class="Bold"><span class="Underline">Inhalation anesthetics:</span></span> Animal experiments have shown that inhalation anesthetics depress cardiovascular activity by decreasing the inward movement of calcium ions. When used concomitantly, inhalation anesthetics and calcium antagonists, such as verapamil, should each be titrated carefully to avoid excessive cardiovascular <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>.</p>
<p><span class="Bold"><span class="Underline">Neuromuscular blocking agents:</span></span> Clinical data and animal studies suggest that verapamil may potentiate the activity of neuromuscular blocking agents (curare-like and depolarizing). It may be necessary to decrease the dose of verapamil and/or the dose of the neuromuscular blocking agent when the drugs are used concomitantly.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="LINK_7e223a41-79b8-40c1-9e40-52870fafd218"></a><a name="section-7.3"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">An 18-month toxicity study in rats, at a low multiple (6-fold) of the maximum recommended human dose, and not the maximum tolerated dose, did not suggest a tumorigenic potential. There was no evidence of a carcinogenic potential of verapamil administered in the diet of rats for two years at doses of 10, 35, and 120 mg/kg/day or approximately 1, 3, 5, and 12 times, respectively, the maximum recommended human daily dose (480 mg/day or 9.6 mg/kg/day).</p>
<p>Verapamil was not mutagenic in the Ames test in 5 test <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> at 3 mg per plate with or without metabolic activation.</p>
<p>Studies in female rats at daily dietary doses up to 5.5 times (55 mg/kg/day) the maximum recommended human dose did not show impaired fertility. Effects on male fertility have not been determined.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="LINK_a97b1567-56f6-43eb-894c-b521a862d98c"></a><a name="section-7.4"></a><p></p>
<h2>Pregnancy</h2>
<p class="First"><span class="Bold">Teratogenic effects: </span>Pregnancy Category C. Reproduction studies have been performed in rabbits and rats at oral doses up to 1.5 (15 mg/kg/day) and 6 (60 mg/kg/day) times the human oral daily dose, respectively, and have revealed no evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span>. In the rat, however, this multiple of the human dose was embryocidal and retarded fetal growth and development, probably because of adverse maternal effects reflected in reduced <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gains</span> of the dams. This oral dose has also been shown to cause <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> in rats. There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. Verapamil crosses the placental barrier and can be detected in umbilical vein blood at delivery.</p>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="LINK_0a5e9de4-60ec-4f4f-9dd2-53b48edc29e0"></a><a name="section-7.5"></a><p></p>
<h2>Labor and Delivery</h2>
<p class="First">It is not known whether the use of verapamil during labor or delivery has immediate or delayed adverse effects on the fetus, or whether it prolongs the duration of labor or increases the need for forceps delivery or other obstetric intervention. Such adverse experiences have not been reported in the literature, despite a long history of use of verapamil in Europe in the treatment of cardiac side effects of beta-adrenergic agonist agents used to treat <span class="product-label-link" type="condition" conceptid="4273560" conceptname="Premature labor">premature labor</span>.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="LINK_33eeaf8f-88e9-4e6d-a3d8-2688f62e0fe0"></a><a name="section-7.6"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Verapamil is excreted in human milk. Because of the potential for adverse reaction in nursing infants from verapamil, nursing should be discontinued while verapamil is administered.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="LINK_699a9db3-1d92-48fc-803a-d1030997a938"></a><a name="section-7.7"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="LINK_eb8975fb-2645-4cab-9963-51f4a6f3a67b"></a><a name="section-8"></a><p></p>
<h1>ANIMAL PHARMACOLOGY AND/OR ANIMAL TOXICOLOGY</h1>
<p class="First">In chronic animal toxicology studies verapamil caused lenticular and/or suture line changes at 30 mg/kg/day or greater, and frank <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataracts</span> at 62.5 mg/kg/day or greater in the beagle dog but not in the rat. Development of <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataracts</span> due to verapamil has not been reported in man.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="LINK_98b83e96-43c8-437d-acb0-849023bf0da6"></a><a name="section-9"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Serious adverse reactions are uncommon when verapamil hydrochloride therapy is initiated with upward dose titration within the recommended single and total daily dose. See <a href="#LINK_edcbe031-4dbb-41e3-a9ae-93862738a56a">WARNINGS</a> for discussion of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, elevated liver enzymes, <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">AV block</span>, and rapid ventricular response. Reversible (upon discontinuation of verapamil) non-obstructive, <span class="product-label-link" type="condition" conceptid="192357" conceptname="Paralytic ileus">paralytic ileus</span> has been infrequently reported in association with the use of verapamil. The following reactions to orally administered verapamil occurred at rates greater than 1% or occurred at lower rates but appeared clearly drug-related in clinical trials in 4,954 patients:</p>
<table frame="box">
<col>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top">  <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">  7.3%</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">  <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">  1.4%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top">  <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">  3.3%</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">  <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">  </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top">  <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">  2.7%</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">  (HR&lt;50/min)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">  1.4%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top">  <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">  2.5%</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">  <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">AV block</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">  </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top">  <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">  2.2%</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">       total (1°, 2°, 3°)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">  1.2%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top">  <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">  1.9%</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">       2° and 3°</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">  0.8%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top">  CHF,<span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">Pulmonary edema</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">  1.8%</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">  <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">  1.2%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top">  <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">  1.7%</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">  <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">Flushing</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">  0.6%</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top">  Elevated liver enzymes(see <a href="#LINK_edcbe031-4dbb-41e3-a9ae-93862738a56a">WARNINGS</a>)	</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">  </td>
<td class="Botrule Lrule Rrule Toprule" valign="top">  </td>
<td class="Botrule Lrule Rrule Toprule" valign="top">  </td>
</tr>
</tbody>
</table>
<p>In clinical trials related to the control of ventricular response in digitalized patients who had <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span> or flutter, ventricular rates below 50 at rest occurred in 15% of patients and asymptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> occurred in 5% of patients.</p>
<p>The following reactions, reported in 1% or less of patients, occurred under conditions (open trials, marketing experience) where a causal relationship is uncertain; they are listed to alert the physician to a possible relationship:</p>
<p><span class="Italics">Cardiovascular: </span> <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>, atrioventricular dissociation, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="442774" conceptname="Intermittent claudication">claudication</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span> (<span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span>), <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>.</p>
<p><span class="Italics">Digestive system:  </span><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, gastrointestinal distress, gingival <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span>.</p>
<p><span class="Italics">Hemic and lymphatic:  </span><span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">ecchymosis</span> or <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span>.</p>
<p><span class="Italics">Nervous system:  </span><span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">cerebrovascular accident</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, equilibrium disorders, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle cramps</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> symptoms, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">shakiness</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>.</p>
<p><span class="Italics">Skin:</span>  <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span> and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">exanthema</span>, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">hair loss</span>, <span class="product-label-link" type="condition" conceptid="4098436" conceptname="Hyperkeratosis">hyperkeratosis</span>, maculae, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>.</p>
<p><span class="Italics">Special senses: </span> <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>.</p>
<p><span class="Italics">Urogenital: </span><span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynecomastia</span>, <span class="product-label-link" type="condition" conceptid="79884" conceptname="Galactorrhea not associated with childbirth">galactorrhea</span>/<span class="product-label-link" type="condition" conceptid="4030186" conceptname="Hyperprolactinemia">hyperprolactinemia</span>, increased urination, spotty menstruation, <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_53377e12-002e-431e-a45c-4192dcf7db75"></a><a name="section-9.1"></a><p></p>
<h2>Treatment of acute cardiovascular adverse reactions</h2>
<p class="First">The frequency of cardiovascular adverse reactions that require therapy is rare; hence, experience with their treatment is limited. Whenever severe <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> or complete <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">AV block</span> occurs following oral administration of verapamil, the appropriate emergency measures should be applied immediately; e.g., intravenously administered norepinephrine bitartrate, atropine sulfate, isoproterenol hydrochloride (all in the usual doses), or calcium gluconate (10% injection). In patients with <span class="product-label-link" type="condition" conceptid="4124693" conceptname="Hypertrophic cardiomyopathy">hypertrophic cardiomyopathy</span> (<span class="product-label-link" type="condition" conceptid="4124693" conceptname="Hypertrophic cardiomyopathy">IHSS</span>), alpha-adrenergic agents (phenylephrine hydrochloride, metaraminol bitartrate, or methoxamine hydrochloride) should be used to maintain blood pressure, and isoproterenol and norepinephrine should be avoided. If further support is necessary, dopamine hydrochloride or dobutamine hydrochloride may be administered. Actual treatment and dosage should depend on the severity of the clinical situation and the judgment and experience of the treating physician.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="LINK_3ce20d87-ca48-4a72-9d74-1075bbfdfa12"></a><a name="section-10"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Treat all verapamil <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> as serious and maintain observation for at least 48 hours (especially the extended-release formulation), preferably under continuous hospital care. Delayed pharmacodynamic consequences may occur with the extended-release formulation. Verapamil is known to decrease gastrointestinal transit time.</p>
<p>Treatment of overdosage should be supportive. Beta-adrenergic stimulation or parenteral administration of calcium injection may increase calcium ion flux across the slow channel, and have been used effectively in treatment of deliberate overdosage with verapamil. In a few reported cases, <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with calcium channel blockers has been associated with <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, initially refractory to atropine but becoming more responsive to this treatment when the patients received large doses (close to 1 gram/hour for more than 24 hours) of calcium chloride. Verapamil cannot be removed by hemodialysis. Clinically significant hypotensive reactions or fixed high-degree <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">AV block</span> should be treated with vasopressor agents or cardiac pacing, respectively. <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">Asystole</span> should be handled by the usual measures, including cardiopulmonary resuscitation.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="LINK_5cf7dbe5-4c0a-42b6-b68c-18fe2fc44a8c"></a><a name="section-11"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">The dose of verapamil hydrochloride must be individualized by titration. The usefulness and safety of dosages exceeding 480 mg/day have not been established; therefore, this daily dosage should not be exceeded. Since the half-life of verapamil increases during chronic dosing, maximum response may be delayed.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_7ff9da50-353a-4b09-8b90-a3370b9c992a"></a><a name="section-11.1"></a><p></p>
<h2>Angina</h2>
<p class="First">Clinical trials show that the usual dose is 80 mg to 120 mg three times a day. However, 40 mg three times a day may be warranted in patients who may have an increased response to verapamil (e.g., decreased hepatic function, elderly, etc.). Upward titration should be based on therapeutic efficacy and safety evaluated approximately eight hours after dosing. Dosage may be increased at daily (e.g., patients with <span class="product-label-link" type="condition" conceptid="315296" conceptname="Preinfarction syndrome">unstable angina</span>) or weekly intervals until optimum clinical response is obtained.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_4f621a08-b048-442b-9126-bdffb7784968"></a><a name="section-11.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Arrhythmias</span></h2>
<p class="First">The dosage in digitalized patients with <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">chronic atrial fibrillation</span> (see <a href="#LINK_a6e74a32-533b-43a2-b01a-36edd6622d06">PRECAUTIONS</a>) ranges from 240 to 320 mg/day in divided (t.i.d. or q.i.d.) doses. The dosage for prophylaxis of PSVT (non-digitalized patients) ranges from 240 to 480 mg/day in divided (t.i.d. or q.i.d.) doses. In general, maximum effects for any given dosage will be apparent during the first 48 hours of therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_ce6e78f9-e911-46e3-b722-480d0ede9d37"></a><a name="section-11.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="320128" conceptname="Essential hypertension">Essential Hypertension</span></h2>
<p class="First">Dose should be individualized by titration. The usual initial monotherapy dose in clinical trials was 80 mg three times a day (240 mg/day). Daily dosages of 360 and 480 mg have been used but there is no evidence that dosages beyond 360 mg provided added effect. Consideration should be given to beginning titration at 40 mg three times per day in patients who might respond to lower doses, such as the elderly or people of small stature. The antihypertensive effects of verapamil are evident within the first week of therapy. Upward titration should be based on therapeutic efficacy, assessed at the end of the dosing interval.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="LINK_b0007e99-b572-47b4-a2ef-a80442773be3"></a><a name="section-12"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Verapamil Hydrochloride Tablets USP, 80 mg white, scored tablets, debossed with <span class="Bold">WATSON 343</span> are available in blistercards of 30.</p>
<p>Verapamil Hydrochloride Tablets USP, 120 mg white, scored tablets, debossed with <span class="Bold">WATSON 345 </span>are available in blistercards of 30.</p>
<p>Dispense in a tight, light-resistant container with child-resistant closure.</p>
<p>Store at 20°-25°C (68°-77°F). [See USP controlled room temperature.]</p>
<p>Manufactured By:<br><span class="Bold">Watson Pharma Private Limited <br></span>Verna, Salcette Goa 403 722 INDIA<br><br>Distributed By:<br><span class="Bold">Watson Pharma, Inc.<br></span>Corona, CA 92880 USA<span class="Bold"><br></span><span class="Bold"><br></span>Revised: November 2008                1108B<span class="Bold"><br></span>                                                        174388</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_0aeda8b0-8dec-44e4-9ca8-ff38fb01d076"></a><a name="section-13"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<p class="First">NDC 0615-7618-39</p>
<p><span class="Bold">Verapamil<br>Hydrochloride<br>Tablets USP<br></span>80 mg</p>
<div class="Figure">
<img alt="Principal Display Panel-Verapamil Hydrochloride Tablets, USP 80mg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0c604923-4a37-45ac-ad93-3610a5eadc16&amp;name=verapamil-hydrochloride-tablets-2.jpg"><p class="MultiMediaCaption"></p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_70cf616e-0317-4c9e-bf59-c0072df71fc2"></a><a name="section-14"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<p class="First">NDC 0615-7619-39</p>
<p><span class="Bold">Verapamil<br>Hydrochloride<br>Tablets USP<br></span>120 mg</p>
<p><span class="Bold"><img alt="Verapamil Hydrochloride Tablets 120mg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0c604923-4a37-45ac-ad93-3610a5eadc16&amp;name=verapamil-hydrochloride-tablets-3.jpg"></span></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>VERAPAMIL HYDROCHLORIDE 		
					</strong><br><span class="contentTableReg">verapamil hydrochloride tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0615-7618(NDC:0591-0343)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>VERAPAMIL HYDROCHLORIDE</strong> (VERAPAMIL) </td>
<td class="formItem">VERAPAMIL HYDROCHLORIDE</td>
<td class="formItem">80 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ANHYDROUS LACTOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLACRILIN POTASSIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 400</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">9mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">WATSON;343</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0615-7618-39</td>
<td class="formItem">30  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA070995</td>
<td class="formItem">10/01/1986</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>VERAPAMIL HYDROCHLORIDE 		
					</strong><br><span class="contentTableReg">verapamil hydrochloride tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0615-7619(NDC:0591-0345)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>VERAPAMIL HYDROCHLORIDE</strong> (VERAPAMIL) </td>
<td class="formItem">VERAPAMIL HYDROCHLORIDE</td>
<td class="formItem">120 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ANHYDROUS LACTOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLACRILIN POTASSIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 400</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">11mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">WATSON;345</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0615-7619-39</td>
<td class="formItem">30  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA070994</td>
<td class="formItem">10/01/1986</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>NCS HealthCare of KY, Inc dba Vangard Labs
							(050052943)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NCS HealthCare of KY, Inc dba Vangard Labs</td>
<td class="formItem"></td>
<td class="formItem">050052943</td>
<td class="formItem">RELABEL(0615-7618, 0615-7619), REPACK(0615-7618, 0615-7619)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 6/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>4ca4589b-28bd-4f8d-b1e8-3a4ba4323253</div>
<div>Set id: 0c604923-4a37-45ac-ad93-3610a5eadc16</div>
<div>Version: 3</div>
<div>Effective Time: 20120618</div>
</div>
</div> <div class="DistributorName">NCS HealthCare of KY, Inc dba Vangard Labs</div></p>
</body></html>
